The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
Open accessAbstract
Genomic instability remains an enabling feature of cancer and promotes malignant transformation. Alterations of DNA damage response (DDR) pathways allow genomic instability, generate neoantigens, upregulate the expression of programmed death ligand 1 (PD-L1) and interact with signaling such as cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling. Here, we review the basic knowledge of DDR pathways, mechanisms of genomic instability induced by DDR alterations, impacts of DDR alterations on immune system, and the potential applications of DDR alterations as biomarkers and therapeutic targets in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Mechanism of Eukaryotic Homologous Recombination
San Filippo, J., Sung, P., & Klein, H. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061306.125255 · Cited by 1,681
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Endogenous DNA damage as a source of genomic instability in cancer
Tubbs, A., & Nussenzweig, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.002 · Cited by 1,452
The multifaceted mismatch-repair system
Jiricny, J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1907 · Cited by 1,370
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Base-excision repair of oxidative DNA damage
David, S. S., O'Shea, V. L., & Kundu, S. (2007) · Nature · doi:10.1038/nature05978 · Cited by 1,238
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 987
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Replication stress links structural and numerical cancer chromosomal instability
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E., et al. (2013) · Nature · doi:10.1038/nature11935 · Cited by 878
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
The Breast Cancer Susceptibility Collaboration (UK), Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., North, B., Jayatilake, H., Barfoot, R., et al. (2006) · Nature Genetics · doi:10.1038/ng1837 · Cited by 743
The mechanism of human nonhomologous DNA end joining
Lieber, M. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r700039200 · Cited by 720
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 702
Mechanisms and therapeutic implications of hypermutation in gliomas
Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C. L., Cortes-Ciriano, I., Birzu, C., Geduldig, J. E., Pelton, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2209-9 · Cited by 677
cGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
Self-citationDNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
Murr, R., Loizou, J. I., Yang, Y.-G., Cuenin, C., Li, H., Wang, Z.-Q., & Herceg, Z. (2006) · Nature Cell Biology · doi:10.1038/ncb1343 · Cited by 613
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563
Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544
Polak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E., et al. (2013) · Nature · doi:10.1038/nature12369 · Cited by 451
STING: a master regulator in the cancer-immunity cycle
Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1087-y · Cited by 431
23 Genetic instability induced by the tumor microenvironment
Glazer, P. M., Reynolds, T. Y., & Rockwell, S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)80581-0 · Cited by 427
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 380
Postreplicative Mismatch Repair
Jiricny, J. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012633 · Cited by 344
Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs
Bindra, R. S., Gibson, S. L., Meng, A., Westermark, U., Jasin, M., Pierce, A. J., Bristow, R. G., Classon, M. K., & Glazer, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2119 · Cited by 334
Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity
Hou, L., Tian, C., Yan, Y., Zhang, L., Zhang, H., & Zhang, Z. (2020) · ACS Nano · doi:10.1021/acsnano.9b06111 · Cited by 309
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y.-A., Schapiro, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15315-8 · Cited by 299
Homologous recombination in cancer development, treatment and development of drug resistance
Helleday, T. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq064 · Cited by 291
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 285
Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells
Mihaylova, V. T., Bindra, R. S., Yuan, J., Campisi, D., Narayanan, L., Jensen, R., Giordano, F., Johnson, R. S., Rockwell, S., & Glazer, P. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.9.3265-3273.2003 · Cited by 274
He, Y., Yu, H., Rozeboom, L., Rivard, C. J., Ellison, K., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 268
Self-citationWang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1814 · Cited by 241
The DNA Damage Response Induces IFN
Brzostek-Racine, S., Gordon, C., Van Scoy, S., & Reich, N. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100040 · Cited by 234
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown, J. S., Sundar, R., & Lopez, J. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.376 · Cited by 231
Biomarker-Guided Development of DNA Repair Inhibitors
Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D’Andrea, A. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.035 · Cited by 225
(2000) · PubMed · Cited by 207
Nava Rodrigues, D., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B., Seed, G., Mateo, J., Riisnaes, R., Mullane, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121924 · Cited by 203
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
Dillon, M. T., Bergerhoff, K. F., Pedersen, M., Whittock, H., Crespo-Rodriguez, E., Patin, E. C., Pearson, A., Smith, H. G., Paget, J. T. E., Patel, R. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1821 · Cited by 199
Vendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198
Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 197
Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored
Li, S. K. H., & Martin, A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.003 · Cited by 191
The role of neoantigens in response to immune checkpoint blockade
Riaz, N., Morris, L., Havel, J. J., Makarov, V., Desrichard, A., & Chan, T. A. (2016) · International Immunology · doi:10.1093/intimm/dxw019 · Cited by 175
Targeting the replication stress response in cancer
Forment, J. V., & O’Connor, M. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.005 · Cited by 170
Figueiredo, C. R., Kalirai, H., Sacco, J. J., Azevedo, R., Duckworth, A. D., Slupsky, J. R., Coulson, J. M., & Coupland, S. E. (2020) · The Journal of Pathology · doi:10.1002/path.5384 · Cited by 167
Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia
Bindra, R. S., & Glazer, P. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210001 · Cited by 161
Huang, J., Wang, L., Cong, Z., Amoozgar, Z., Kiner, E., Xing, D., Oršulić, S., Matulonis, U. A., & Goldberg, M. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.083 · Cited by 153
Self-citationLesterhuis, W. J., Salmons, J., Nowak, A. K., Rozali, E. N., Khong, A., Dick, I. M., Harken, J. A., Robinson, B. W. S., & Lake, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061895 · Cited by 152
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Shrestha, R., Nabavi, N., Lin, Y., Mo, F., Anderson, S. A., Volik, S. V., Adomat, H. H., Lin, D., Xue, H., Dong, X., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0620-3 · Cited by 152
Heijink, A. M., Talens, F., Jae, L. T., van Gijn, S. E., Fehrmann, R. S. N., Brummelkamp, T. R., & van Vugt, M. A. T. M. (2019) · Nature Communications · doi:10.1038/s41467-018-07927-y · Cited by 140
Base excision repair regulates PD-L1 expression in cancer cells
Permata, T. B. M., Hagiwara, Y., Sato, H., Yasuhara, T., Oike, T., Gondhowiardjo, S. A., Held, K. D., Nakano, T., & Shibata, A. (2019) · Oncogene · doi:10.1038/s41388-019-0733-6 · Cited by 105
Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH
Glazer, P. M., Yuan, J., Rockwell, S., & Narayanan, L. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)80378-8 · Cited by 103
Chae, H., Kim, D., Yoo, C., Kim, K., Jeong, J. H., Chang, H.-M., Lee, S. S., Park, D. H., Song, T. J., Hwang, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.022 · Cited by 98
Bono, J. S. D., Goh, J. C. H., Ojamaa, K., Rodriguez, J. M. P., Drake, C. G., Hoimes, C. J., Wu, H., Poehlein, C. H., & Antonarakis, E. S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5007 · Cited by 97
Mechanisms of genome instability induced by RNA-processing defects
Chan, Y. A., Hieter, P., & Stirling, P. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.03.005 · Cited by 96
Vidotto, T., Nersesian, S., Graham, C. H., Siemens, D. R., & Koti, M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0619-8 · Cited by 85
Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
Gaston, J., Cheradame, L., Yvonnet, V., Déas, O., Poupon, M., Judde, J., Cairo, S., & Goffin, V. (2016) · Oncotarget · doi:10.18632/oncotarget.12858 · Cited by 79
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Ladanyi, M., Sánchez-Vega, F., & Zauderer, M. G. (2019) · Genome Medicine · doi:10.1186/s13073-019-0631-0 · Cited by 69
Suh, W., Tafuri, A., Berg-Brown, N. N., Shahinian, A., Plyte, S., Duncan, G. S., Okada, H., Wakeham, A. C., Odermatt, B., Ohashi, P. S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5917 · Cited by 68
Mutation of NIMA-related kinase 1 (NEK1) leads to chromosome instability
Chen, Y., Chen, C., Chiang, H.-C., Pena, M. J., Polci, R., Wei, R. L.-H., Edwards, R. A., Hansel, D. E., Chen, P., & Riley, D. J. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-5 · Cited by 67
Rationale for stimulator of interferon genes–targeted cancer immunotherapy
Vargas, T. R., Benoit-Lizon, I., & Apétoh, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.028 · Cited by 67
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
Beebe‐Dimmer, J., Kapron, A. L., Fraser, A. M., Smith, K. R., & Cooney, K. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02808 · Cited by 65
Hauschild, A., Eichstaedt, J., Möbus, L., Kähler, K. C., Weichenthal, M., Schwarz, T., & Weidinger, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.026 · Cited by 61
DNA excision repair at telomeres
Jia, P., Her, C., & Chai, W. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.09.017 · Cited by 55
Rodrigues, D. N., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B. K., Seed, G., Mateo, J., Riisnaes, R., Mullane, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125184 · Cited by 54
The role of MYH and microsatellite instability in the development of sporadic colorectal cancer
Colebatch, A. J., Hitchins, M. P., Williams, R., Meagher, A. P., Hawkins, N. J., & Ward, R. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603421 · Cited by 52
Patel, P., Sun, L., Robbins, Y. L., Clavijo, P. E., Friedman, J., Silvin, C. J., Waes, C. V., Cook, J. A., Mitchell, J. B., & Allen, C. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638207 · Cited by 48
Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions
Chene, G., Tchirkov, A., Eymard-Pierre, É., Dauplat, J., Raoelfils, I., Cayre, A., Watkin, E., Vago, P., & Penault-Llorca, F. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3947 · Cited by 44
DNA Repair Deficiency and Immunotherapy Response
Mouw, K. W., & D’Andrea, A. D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2425 · Cited by 42
Zhang, B., Lyu, J., Yang, E. J., Liu, Y., Wu, C., Pardeshi, L. A., Tan, K., Chen, Q., Xu, X., Deng, C., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.008 · Cited by 40
Self-citationDramatic response to nivolumab in xeroderma pigmentosum skin tumor
Chambon, F., Osdoit, S., Bagny, K., Moro, A., Nguyen, J., & Réguerre, Y. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26837 · Cited by 30
Das, S., Camphausen, K. A., & Shankavaram, U. T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01136 · Cited by 14
Aiello, M. M., Solinas, C., Santoni, M., Battelli, N., Restuccia, N., Latteri, F., Paratore, S., Verderame, F., Albanese, G. V., Bruzzi, P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01167 · Cited by 14
Kraemer, K. H., Tamura, D., & Khan, S. G. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16525 · Cited by 8
DNA-repair enzyme turns to translation
Warren, A. J. (2020) · Nature · doi:10.1038/d41586-020-00424-7 · Cited by 3
Kraemer, K. H. (1994) · Archives of Dermatology · doi:10.1001/archderm.1994.01690080084012 · Cited by 1
Cited by
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
Wang, Y., Ju, X., Hua, R., Chen, J., Dai, X., Liu, L., Wang, G., Bai, Y., Hu, H., & Li, X. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02856-8 · Cited by 18
Metadata
- Authors
- Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 11
- Issue
- 10
- Pages
- 2983-2994
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3119518737
- Cited by
- 320
- References
- 103
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.